Skip to main content

Table 2 Disease characteristics measured during reversibility testing and at baseline (treated set)

From: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids

  Reversibility testing  
Pre-bronchodilator a Post-bronchodilator b Baseline pre-dose c
Mean SD Mean SD Mean SD
FEV1       
  Predicted normal, L 1.928 0.416     
  Actual, L 1.539 0.385 1.909 0.469 1.640 0.386
  Actual, % predicted normal 79.661 8.142 98.908 11.024 85.392 10.711
  Reversibility, mLd    370 171   
  Reversibility, % of pre-bronchodilatore    24.578 12.106   
  Variation, %f      7.60 12.43
FVC 2.233 0.519     
  Predicted normal, L 2.059 0.567 2.341 0.611   
  Actual, L 92.266 13.339 105.080 15.560 2.127 0.545
  Actual, % predicted normal 75.830 9.623 82.404 8.817 95.844 15.067
FEV1/FVC, %      78.109 9.467
PEF, L/min      220 56
ICS maintenance dose, μg (budesonide or equivalent dose)      282.2 85.8
  1. aMeasured 10 minutes prior to inhalation of two puffs of salbutamol (100 μg per puff) at screening (Visit 1); bMeasured 15–30 minutes after inhalation of two puffs of salbutamol (100 μg per puff) at screening (Visit 1); cMeasured 10 minutes prior to inhalation of study medication at baseline (Visit 2); dCalculated as FEV1 post-bronchodilator – FEV1 pre-bronchodilator; eCalculated as 100 × (FEV1 post-bronchodilator/FEV1 pre-bronchodilator) – 1; fCalculated as 100 × (FEV1 at baseline/pre-bronchodilator FEV1 at screening) – 1. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids; PEF, peak expiratory flow; SD, standard deviation.